Synairgen plc Result of AGM (9528A)
June 03 2019 - 5:52AM
UK Regulatory
TIDMSNG
RNS Number : 9528A
Synairgen plc
03 June 2019
Press release
Synairgen plc
('Synairgen' or the 'Company')
Result of AGM
Southampton, UK - 03 June 2019: Synairgen (LSE: SNG), the
respiratory drug discovery and development company, is pleased to
announce that all resolutions proposed at its Annual General
Meeting, held earlier today, were duly passed.
As announced on 18 April 2019, Paul Clegg has retired from the
Board as a non-executive director, effective on 3 June 2019
(today).
- Ends -
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Max Bullen-Smith (Corporate Finance)
Alice Lane (ECM)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott, Sue Stuart, Olivia Manser
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on asthma and COPD, uses its differentiating human
biology BioBank platform and world-renowned international academic
KOL network to discover and develop novel therapies for respiratory
disease. Leveraging its scientific and clinical facilities at
Southampton General Hospital, the Company uses in vitro and ex vivo
models to progress opportunities into clinical development. The
BioBank of human samples is used in these models to increase
confidence in the likelihood of successful drug development.
Synairgen is currently conducting a two-part Phase II trial
evaluating SNG001, the Company's inhaled interferon beta (IFN-beta)
product. The Phase II trial, called SG015, has been designed to
assess the safety of SNG001 in COPD patients and its clinical
benefit in these patients when they have a cold or flu infection, a
major driver of COPD exacerbations.
Core to Synairgen's business strategy is the realisation of
value via licensing transactions. In August 2015 the Company
entered into a collaboration with Pharmaxis to develop an oral
LOXL2 inhibitor to reduce fibrosis in patients with idiopathic
pulmonary fibrosis (IPF). In December 2017, the collaboration
agreement was amended as Pharmaxis took on full responsibility for
the programme, with Synairgen receiving a GBP5 million upfront
payment and a share of at least 17% (net of allowable expenses) of
any receipts from any onward licensing by Pharmaxis of the LOXL2
inhibitors in fibrotic indications.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGBGGDLCSGBGCX
(END) Dow Jones Newswires
June 03, 2019 06:52 ET (10:52 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2024 to May 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From May 2023 to May 2024